Recently, advances in wearable technologies, data science and machine learning have
begun to transform evidence-based medicine, offering a tantalizing glimpse into a future of …

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal
growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly develo** a
strong evidence base for use in patients with cancer. The European Society for Medical …

Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …

Historically, studies of disseminated tumour cells in bone marrow and circulating tumour
cells in peripheral blood have provided crucial insights into cancer biology and the …

Breast cancer is the most common cancer and the deadliest among women worldwide.
Estrogen signaling is closely associated with hormone-dependent breast cancer (estrogen …

Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …

In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …

Background Capivasertib, an AKT inhibitor, added to fulvestrant, was previously reported to
improve progression-free survival in women with aromatase inhibitor-resistant oestrogen …